Cargando…
Glucosylceramide synthase inhibition protects against cardiac hypertrophy in chronic kidney disease
A significant population of patients with chronic kidney disease (CKD) develops cardiac hypertrophy, which can lead to heart failure and sudden cardiac death. Soluble klotho (sKL), the shed ectodomain of the transmembrane protein klotho, protects the heart against hypertrophic growth. We have shown...
Autores principales: | Baccam, Gabriel C., Xie, Jian, Jin, Xin, Park, Hyejung, Wang, Bing, Husson, Hervé, Ibraghimov-Beskrovnaya, Oxana, Huang, Chou-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167280/ https://www.ncbi.nlm.nih.gov/pubmed/35660779 http://dx.doi.org/10.1038/s41598-022-13390-z |
Ejemplares similares
-
Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease
por: Natoli, Thomas A., et al.
Publicado: (2012) -
Polycystic kidney diseases: From molecular discoveries to targeted therapeutic strategies
por: Ibraghimov-Beskrovnaya, O., et al.
Publicado: (2007) -
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model
por: Viel, Catherine, et al.
Publicado: (2021) -
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016) -
Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD
por: Rogers, Kelly A., et al.
Publicado: (2016)